tradingkey.logo

Health Canada Approves Ozempic® To Reduce The Risk Of Sustained Egfr Decline, End-Stage Kidney Disease, And Cardiovascular Death In Adults With Type 2 Diabetes And Chronic Kidney Disease

ReutersAug 19, 2025 11:39 AM

- Novo Nordisk A/S NOVOb.CO:

  • HEALTH CANADA APPROVES OZEMPIC® TO REDUCE THE RISK OF SUSTAINED EGFR DECLINE, END-STAGE KIDNEY DISEASE, AND CARDIOVASCULAR DEATH IN ADULTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE

  • NOVO NORDISK CANADA: HEALTH CANADA'S CKD INDICATION FOR OZEMPIC IS BASED ON RESULTS OF FLOW TRIAL

Further company coverage: [NOVOb.CO]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI